Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/j.1365-2036.2006.03240.x http://scihub22266oqcxt.onion/10.1111/j.1365-2036.2006.03240.x 17305755!ä!17305755 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Aliment+Pharmacol+Ther 2007 ; 25 (5): 537-56 Nephropedia Template TP {{tp|p=17305755|t=2007. Meta-analysis: randomized controlled trials of clindamycin/aminoglycoside vs beta-lactam monotherapy for the treatment of intra-abdominal infections |pdf=|usr=}}{{17305755}} gab.com Text Meta-analysis: randomized controlled trials of clindamycin/aminoglycoside vs beta-lactam monotherapy for the treatment of intra-abdominal infections JO: Aliment Pharmacol Ther http://www.kidney.de/pget.php?&tw=1&pmid=17305755 #FOAvip AIM: To compare the effectiveness and safety of clindamycin/aminoglycoside with broad-spectrum beta-lactam monotherapy in patients with intra-abdominal infections by performing a meta-analysis of randomized controlled trials (RCTs). METHODS: The relevant 28 RCTS were retrieved from PubMed searches and reviewed by two reviewers independently. RESULTS: beta-lactam monotherapy was more effective regarding cure of the infection than clindamycin/aminoglycoside (3177 clinically evaluable patients, fixed effects model, OR = 0.67, 95% CI: 0.55-0.81). The same result was found in several subset analyses. There was no difference in all-cause mortality and attributable-to-infection mortality [2382 intention-to-treat (ITT) patients, fixed effects model, OR = 1.25, 95% CI: 0.74-2.11 and 1976 ITT patients, OR = 1.19, 95% CI: 0.59-2.41, respectively]. There was no difference regarding overall adverse events and ototoxicity (1460 ITT patients, OR = 1.05, 95% CI: 0.80-1.37, and 1404 ITT patients, OR = 3.22, 95% CI: 0.72-14.45, respectively). However, treatment with clindamycin/aminoglycoside was more likely to be associated with nephrotoxicity compared to beta-lactam (3065 ITT patients, OR = 3.7, 95% CI: 2.09-6.57). Clindamycin/aminoglycoside was less likely to be associated with antibiotic-associated diarrhoea compared to beta-lactam (3050 ITT patients, OR = 0.68, 95% CI: 0.46-1.00). CONCLUSION: The results of our meta-analysis suggest that beta-lactams are more effective in the treatment of intra-abdominal infections compared with clindamycin/aminoglycoside. Twit Text FOAVip Meta-analysis: randomized controlled trials of clindamycin/aminoglycoside vs beta-lactam monotherapy for the treatment of intra-abdominal infections ????Aliment Pharmacol Ther http://www.kidney.de/pget.php?&tw=1&pmid=17305755 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=17305755 #FOAvip English Wikipedia <ref>{{Cite pmid|17305755}}</ref> Meta-analysis: randomized controlled trials of clindamycin/aminoglycoside vs beta-lactam monotherapy for the treatment of intra-abdominal infections #MMPMID17305755 Falagas ME; Matthaiou DK; Karveli EA; Peppas G Aliment Pharmacol Ther 2007[Mar]; 25 (5): 537-56 PMID17305755show ga AIM: To compare the effectiveness and safety of clindamycin/aminoglycoside with broad-spectrum beta-lactam monotherapy in patients with intra-abdominal infections by performing a meta-analysis of randomized controlled trials (RCTs). METHODS: The relevant 28 RCTS were retrieved from PubMed searches and reviewed by two reviewers independently. RESULTS: beta-lactam monotherapy was more effective regarding cure of the infection than clindamycin/aminoglycoside (3177 clinically evaluable patients, fixed effects model, OR = 0.67, 95% CI: 0.55-0.81). The same result was found in several subset analyses. There was no difference in all-cause mortality and attributable-to-infection mortality [2382 intention-to-treat (ITT) patients, fixed effects model, OR = 1.25, 95% CI: 0.74-2.11 and 1976 ITT patients, OR = 1.19, 95% CI: 0.59-2.41, respectively]. There was no difference regarding overall adverse events and ototoxicity (1460 ITT patients, OR = 1.05, 95% CI: 0.80-1.37, and 1404 ITT patients, OR = 3.22, 95% CI: 0.72-14.45, respectively). However, treatment with clindamycin/aminoglycoside was more likely to be associated with nephrotoxicity compared to beta-lactam (3065 ITT patients, OR = 3.7, 95% CI: 2.09-6.57). Clindamycin/aminoglycoside was less likely to be associated with antibiotic-associated diarrhoea compared to beta-lactam (3050 ITT patients, OR = 0.68, 95% CI: 0.46-1.00). CONCLUSION: The results of our meta-analysis suggest that beta-lactams are more effective in the treatment of intra-abdominal infections compared with clindamycin/aminoglycoside. |Aminoglycosides/*therapeutic use[MESH] |Anti-Bacterial Agents/*therapeutic use[MESH] |Bacterial Infections/*drug therapy[MESH] |Digestive System Diseases/*drug therapy/microbiology[MESH] |Humans[MESH] |Randomized Controlled Trials as Topic[MESH] |Treatment Outcome[MESH]Meta-analysis: randomized controlled trials of clindamycin/aminoglycos(epmc).pdf DeepDyve Pubget Overpricing